Léčba rabdomyosarkomů dětského věku
| Title in English | The rhabdomyosarcoma treatment in children |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Onkologie |
| MU Faculty or unit | |
| Citation | |
| web | https://www.onkologiecs.cz/artkey/xon-201605-0005_Lecba_rabdomyosarkomu_detskeho_veku.php |
| Field | Oncology and hematology |
| Keywords | rhabdomyosarcoma; soft tissue sarcoma; mTOR inhibitor; doxorubicin; irinotecan |
| Description | The rhabdomyosarcoma is the most frequent soft tissue sarcoma in childhood. Current treatment standards are defined by EpSS and COG cooperative groups. Risk adapted treatment is adopted for different prognostic groups of patients with long term overall survival within range of 60–80 %. New treatment options in Europe randomize irinotecan and mTOR inhibitor to standards in high risk and very high risk patients. Maintenance therapy is scheduled for period of 6-24 months according to risk group. Locoregional therapy will be randomized as pre – or postsurgery, standard or higher radiotherapy dose for post induction FDG PET positive patients with tumor size up to 5 cm, all metastatic sites or limited locoregional irradiation for patients with more then three metastatic sites. Relapsed patient will be in Europe randomized to three arms with addition of doxorubicin or temsirolimus to vincristine/irinotecan backbone. COG group defines temsirolimus as better option for relapsed patients compared to bevacizumab. Patients with relapse or high risk metastatic disease should be treated in clinical trial. |
| Related projects: |